Antidepressant- and anxiolytic-like activity of magnesium in mice

Pharmacology Biochemistry and Behavior

Volumn 78, Issue 1, 2004, Pages 7-12

  Poleszak, Ewa ^a   Szewczyk, Bernadeta ^b   Kȩdzierska, Ewa ^a   Wlaź, Piotr ^c   Pilc, Andrzej ^b,d   Nowak, Gabriel ^b,d  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Elevated plus maze; Forced swim test; Locomotor activity; Magnesium; Mice

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MAGNESIUM;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FORCED SWIMMING TEST; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; MAGNESIUM; MALE; MAZE LEARNING; MICE;

EID: 2442690114     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.01.006     Document Type: Article

References (39)

1. Banki C.M., Vojnik M., Papp Z., Balla K.Z., Arato M. Cerebrospinal fluid magnesium and calcium related to amine metabolites, diagnosis, and suicide attempts. Biol. Psychiatry. 20:1985;163-171
2. Decollogne S., Tomas A., Lecerf C., Adamowicz E., Seman M. NMDA receptor complex blockade by oral administration of magnesium: comparison with MK-801. Pharmacol. Biochem. Behav. 58:1997;261-268
3. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur. J. Pharmacol. 169:1989;1-10
4. Hashizume N., Mori M. An analysis of hypermagnesemia and hypomagnesemia. Jpn. J. Med. 29:1990;368-372
5. Hollister L.E., Csernansky J.G. Clinical pharmacology of psychotherapeutic drugs. 3rd ed. 1990;Churchill Livingstone, New York
6. Iannello S., Belfiore F. Hypomagnesemia. A review of pathophysiological, clinical and therapeutical aspects. Panminerva Med. 43:2001;177-209
7. Kroczka B., Zieba A., Dudek D., Pilc A., Nowak G. Zinc exhibits an antidepressant-like effects in the forced swimming test in mice. Pol. J. Pharmacol. 52:2000;403-406
8. Kroczka B., Branski P., Palucha A., Pilc A., Nowak G. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res. Bull. 55:2001;297-300
9. Layer R.T., Popik P., Olds T., Skolnick P. Antidepressant-like actions of the polyamide site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol. Biochem. Behav. 52:1995;621-627
10. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185
11. Maj J., Rogóż Z., Skuza G., Sowińska H. Effects of MK-801 and antidepressant drugs in the forced swimming testing rats. Eur. Neuropsychpharmacol. 2:1992;37a-41a
12. Maj J., Rogóż Z., Skuza G., Sowińska H. The effect of CGP37849 and CGP 39551, competitive NMDA receptor, antagonists in the forced swimming test. Pol. J. Pharmacol. 44:1992;337-346
13. Maj J., Rogóż Z., Skuza G., Kolodziejczyk K. Some central effects of kynurenic acid, 7-chlorokynurenic acid and 5, 7-dichloro-kynurenic acid, glycine side antagonists. Pol. J. Pharmacol. 46:1994;115-124
14. 2+-block site of the NMDA receptor channel. Nature. 358:1992;673-675
15. Morris M.E. Brain and CSF magnesium concentrations during magnesium deficit in animals and humans: neurological symptoms. Magnes. Res. 5:1992;303-313
16. Moryl E., Danysz W., Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol. Toxicol. 72:1993;394-397
17. Murck H. Magnesium and affective disorders. Nutr. Neurosci. 5:2002;375-389
18. Nowak G., Szewczyk B., Wieronska J.M., Branski P., Palucha A., Pilc A., et al. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res. Bull. 61:2003;159-164
19. Ossowska G., Klenk-Majewska B., Szymczyk G. The effects of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats. J. Physiol. Pharmacol. 48:1997;127-135
20. Oswald I., Brezinova V., Dunleavy D.L.F. On the slowness of action of tricyclic antidepressant drugs. Br. J. Psychiatry. 120:1972;673-677
21. Papp M., Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonist in e chronic mild stress model of depression. Eur. J. Pharmacol. 263:1994;1-7
22. Papp M., Moryl E. Antidepressant-like effects of I- aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur. J. Pharmacol. 316:1996;145-151
23. Pavlinac D., Langer R., Lenhard L., Deftos L. Magnesium in affective disorders. Biol. Psychiatry. 14:1979;657-661
24. Pilc A., Klodzinska A., Nowak G. A role of glutamate in the treatment of anxiety and depression: focus on group I metabotropic glutamate (mGlu) receptors. Drugs Future. 27:2002;753-763
25. Plaźnik A., Palejko W., Nazar M., Jessa M. Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur. Neuropsychopharmacol. 4:1994;503-512
26. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229:1997;327-336
27. Przegaliński E., Tatarczyńska E., Dere-Wesolek A., Chojnacka-Wójcik E. Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors. Pharmacol. Biochem. Behav. 54:1996;73-77
28. Przegaliński E., Tatarczyńska E., Deren-Wesolek A., Chojnacka-Wójcik E. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology. 36:1997;31-37
29. Rasmussen H.H., Mortensen P.B., Jensen I.W. Depression and magnesium deficiency. Int. J. Psychiatr. Med. 19:1989;57-63
30. Redmond A.M., Kelly J.P., Leonard B.E. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol. Biochem. Behav. 58:1997;355-359
31. Ryan M.F., Barbour H. Magnesium measurement in routine clinical practice. Ann. Clin. Biochem. 35:1998;449-459
32. Skolnick P. Antidepressants for the new millennium. Eur. J. Pharmacol. 375:1999;31-40
33. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R. Adaptation of N-methyl-D-aspartate receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry. 29:1996;23-26
34. Skolnick P., Legutko B., Li X., Bymaster F.P. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol. Res. 43:2001;411-422
35. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant action. Eur. J. Pharmacol. 185:1990;1-10
36. Vetulani J., Nalepa I. Antidepressants: past, present and future. Eur. J. Pharmacol. 405:2000;351-363
37. Wiley J.L., Cristello A.F., Balster R.L. Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur. J. Pharmacol. 294:1995;101-107
38. Zieba A., Kata R., Dudek D., Schlegel-Zawadzka M., Nowak G. Serum trace elements in animal models and human depression: III. Magnesium. Relationship with copper. Hum. Psychopharmacol. Clin. Exp. 15:2000;631-635
39. Zimmerman M., Mcdermut W., Mattia J.I. Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am. J. Psychiatry. 157:2000;1337-1340